Friday, 16 October 2026European Markets

POLIGHT Stock Is 9% Down So Far Today

Loading stream...

(VIANEWS) - Shares of POLIGHT (Oslo Børs Benchmark Index_GI: PLT.OL) slid 9.42% to kr11.54 at 14:37 EST on Thursday, after four consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 0.27% to kr1,230.91, following the last session's upward trend. This seems, so far, a somewhat bullish trend exchanging session today.

POLIGHT's last close was kr12.74, 56.07% under its 52-week high of kr29.00.

About POLIGHT

poLight ASA develops optical lens for consumer devices and industrial applications in Europe, Asia, and the United States. The company's lens replicates the lens of the human eye enabling the implementation of autofocus functions for various applications. Its product portfolio includes TLens, a tuneable optical lens for autofocus camera applications; Packaged TLens that facilitates integration of a TLens on a fixed-focus camera module; ASIC drivers, which control the supply of variable voltage to Tlens products and makes them to change focus; TLens Silver and TLens Silver Premium devices; and evaluation kits that allows to test and evaluate the optical and electrical performance of the TLens in new products and/or applications. The company serves smartphones and wearables, barcode/industrial, augmented reality, medical endoscopy, webcams, and other markets. poLight ASA was incorporated in 2005 and is headquartered in Skoppum, Norway.

Earnings Per Share

As for profitability, POLIGHT has a trailing twelve months EPS of kr-1.31.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -38.2%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 384.1%, now sitting on 19.01M for the twelve trailing months.

Earnings Before Interest, Taxes, Depreciation, and Amortization

POLIGHT's EBITDA is 27.11.

More news about POLIGHT (PLT.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com